Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 1/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29397600 | 1.00 | GRN (0.55) | GRNSORT1KDM4EMAPTTHRB | |
| SCHEMBL9725956 | 1.00 | GRN (0.55) | GRNSORT1KDM4EMAPTTHRB | |
| SCHEMBL18515857 | 0.86 | GRN (0.56) | GRNSORT1KDM4EMAPTTHRB | |
| SCHEMBL27587952 | 0.83 | GRN (0.54) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL27587953 | 0.83 | GRN (0.54) | GRNSORT1MAPK1PYGLCYP2C9 | |
| SCHEMBL29750216 | 0.83 | GRN (0.54) | GRNSORT1KDM4EMAPTTHRB | |
| SCHEMBL23051973 | 0.81 | GRN (0.39) | GRNSORT1KDM4EMAPTTHRB | |
| SCHEMBL213064 | 0.81 | PPARA (0.53) | GRNSORT1PPARACA1CA2 | |
| SCHEMBL2158663 | 0.81 | PPARA (0.53) | GRNSORT1PPARACA1CA2 | |
| SCHEMBL212031 | 0.81 | PPARA (0.53) | GRNSORT1PPARACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2024-04-18 | — | — | US | disclosed |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2021-09-09 | — | — | US | disclosed |
| US-11026957-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | SRX CARDIO, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200253995-A1 | METHOD TO TREAT HYPERCHOLESTEROLEMIA BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | SRX CARDIO, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10688114-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SXR Cardio, LLC (US) | 2020-06-23 | — | — | US | disclosed |
| US-10307433-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180303855-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC | 2018-10-25 | — | — | US | disclosed |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3182971-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX Cardio, LLC (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016029037-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | GRN 2549/4885SORT1 25/4885KDM4E 3449/4885 |
| US-10307433-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | GRN 2516/4885SORT1 26/4885KDM4E 3501/4885 |
| US-20180303855-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | GRN 2516/4885SORT1 26/4885KDM4E 3501/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | GRN 2549/4885SORT1 25/4885KDM4E 3449/4885 |
| US-20210275551-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | GRN 3387/4885SORT1 38/4885KDM4E 2708/4885 |
| US-20240122951-A1 | METHOD TO TREAT LIPID DYSREGULATION BY MODULATING ACTIVITY OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | GRN 3395/4885SORT1 38/4885KDM4E 2676/4885 |
| US-20200253995-A1 | METHOD TO TREAT HYPERCHOLESTEROLEMIA BY MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PROTEIN ACTIVITY WITH SMALL MOLECULE LIGANDS | PCSK9, LDLR, PCSK7 | GRN 3211/4885SORT1 39/4885KDM4E 2689/4885 |
| US-11026957-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | GRN 3374/4885SORT1 38/4885KDM4E 2709/4885 |
| US-11771710-B2 | Method to treat lipid dysregulation by modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein activity with small molecule ligands | PCSK9, LDLR, PCSK7 | GRN 3374/4885SORT1 38/4885KDM4E 2709/4885 |
| US-10688114-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | GRN 2516/4885SORT1 26/4885KDM4E 3501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.